Clozapine in Treatment-Resistant Bipolar Disorder With Suicidality. Three Case Reports

Alina Wilkowska, Mariusz S Wiglusz, Wiesław J Cubała, Alina Wilkowska, Mariusz S Wiglusz, Wiesław J Cubała

Abstract

Bipolar disorder is associated with a high risk of suicide attempts and suicide deaths. The suicide mortality of people with bipolar disorder is approximately 25 times higher than the general population. No approved pharmacological strategies for suicidal thoughts and attempts in bipolar disorder have been introduced so far, and lithium remains as the first-line treatment for suicidal subjects. Clozapine is also a potentially good candidate for this indication. This case series represents three treatment-resistant bipolar patients with severe suicidal ideation who responded to low-dose clozapine treatment.

Keywords: bipolar depression; bipolar disorder; clozapine; suicidal ideation; treatment resistance.

References

    1. Zarate CA, Jr, Tohen M, Baldessarini RJ. Clozapine in severe mood disorders. J Clin Psychiatry (1995) 56:411–7.
    1. Suppes T, Webb A, Paul B, Carmody T, Kraemer H, Rush AJ. Clinical outcome in a randomized 1-year trial of clozapine versus treatment as usual for patients with treatment-resistant illness and a history of mania. Am J Psychiatry (1999) 156:1164–9.
    1. Kowatch R, Suppes T, Gilfillan SK, Fuentes RM, Grannemann BD, Emslie GJ, et al. Clozapine treatment of children and adolescents with bipolar disorder and schizophrenia: a clinical case series. J Child Adolesc Psychopharmacol (1995) 5:241–53. 10.1089/cap.1995.5.241
    1. Nielsen J, Kane JM, Correll CU. Real-world effectiveness of clozapine in patients with bipolar disorder: results from a 2-year mirror-image study. Bipolar Disord (2012) 14:863–9. 10.1111/bdi.12018
    1. Banov MD, Zarate CA, Jr, Tohen M, Scialabba D, Wines JD, Jr, Kolbrener M, et al. Clozapine therapy in refractory affective disorders: polarity predicts response in long-term follow-up. J Clin Psychiatry (1994) 55:295–300.
    1. Vangala VR, Brown ES, Suppes T. Clozapine associated with decreased suicidality in bipolar disorder: a case report. Bipolar Disord (1999) 1:123–4. 10.1034/j.1399-5618.1999.010210.x
    1. Schaffer A, Isometsä ET, Tondo L, Moreno D, Turecki G, Reis C, et al. International society for bipolar disorders task force on suicide: meta-analyses and meta-regression of correlates of suicide attempts and suicide deaths in bipolar disorder. Bipolar Disord (2015) 17:1–16. 10.1111/bdi.12271
    1. Carter TD, Mundo E, Parikh SV, Kennedy JL. Early age at onset as a risk factor for poor outcome of bipolar disorder. J Psychiatr Res (2003) 37:297–303. 10.1016/S0022-3956(03)00052-9
    1. Baldessarini RJ, Pompili M. Tondo L Bipolar Disorder. In: Simon HI, Hales RE, editors. American Psychiatric Publishing Textbook of Suicide Assessment and Management. American Psychiatric Publishing; (2006). p. 277–99.
    1. Goodwin FK, Jamison KR. Manic-Depressive Illness. New York, NY: Oxford University Press; (1990).
    1. Baldessarini RJ, Pompili M, Tondo L. Suicide in bipolar disorder: risks and management. CNS Spectr (2006) 11(6):465–71. 10.1017/S1092852900014681
    1. Calabrese JR, Kimmel SE, Woyshville MJ, Rapport DJ, Faust CJ, Thompson PA, et al. Clozapine for treatment-refractory mania. J Psychiatry (1996) 153:759–64. 10.1176/ajp.153.6.759
    1. Meltzer HY, Alphs L, Green AI, Altamura AC, Anand R, Bertoldi A, et al. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry (2003) 60:82–91. 10.1001/archpsyc.60.1.82
    1. Hennen J, Baldessarini RJ. Reduced suicidal risk during treatment with clozapine: meta-analysis. Schizophre Res (2005) 73:139–45. 10.1016/j.schres.2004.05.015
    1. Ciapparelli A, Dell’Osso L, Pini S, Chiavacci MC, Fenzi M, Cassano GB. Clozapine for treatment-refractory schizophrenia, schizoaffective disorder, and psychotic bipolar disorder: a 24-month naturalistic study. J Clin Psychiatry (2000) 61:329–34. 10.4088/JCP.v61n0502
    1. Fehr BS, Ozcan ME, Suppes T. Low doses of clozapine may stabilize treatment-resistant bipolar patients. Eur Arch Psychiatry Clin Neurosci (2005) 255:10–4. 10.1007/s00406-004-0528-8
    1. Li X-B, Tang Y-L, Wang C-Y, de Leon J. Clozapine for treatment resistant bipolar disorder: a systematic review. Bipolar Disord (2015) 17:235–47. 10.1111/bdi.12272
    1. Griffiths JJ, Zarate CA, Jr, Rasimas JJ. Existing and novel biological therapeutics in suicide prevention. Am J Prev Med (2014) Sep47(3 Suppl 2):S195–203. 10.1016/j.amepre.2014.06.012
    1. Goodwin GM. Consensus Group of the British Association for Psychopharmacology. Evidence-based guidelines for treating bipolar disorder: revised second edition-recommendations from the British Association for Psychopharmacology. J Psychopharmacol (2009) 23(4):346–88. 10.1177/0269881109102919
    1. Grunze H, Vieta E, Goodwin GM, Bowden C, Licht RW, Moller HJ, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2012 on the long term treatment of bipolar disorder. World J Biol Psychiatry (2013) 14:154–219. 10.3109/15622975.2013.770551
    1. Yatham LN, Kennedy SH, Schaffer A, Parikh SV, Beaulieus S, O'Donovan C, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. Bipolar Disord (2009) 11:225–55. 10.1111/j.1399-5618.2009.00672.x
    1. Nielsen J, Dahm M, Lublin H, Taylor D. Psychiatrists’ attitude towards and knowledge of clozapine treatment. J Psychopharmacol (2010) 24:965–71. 10.1177/0269881108100320
    1. Meltzer HY, Anand R, Alphs L. Reducing suicide risk in schizophrenia: focus on the role of clozapine. CNS Drugs (2000) 14:355–65. 10.2165/00023210-200014050-00003
    1. Marx CE, Shampine LJ, Duncan GE, Van Doren MJ, Grobin AC, Massing MW, et al. Clozapine markedly elevates pregnenolone in rat hippocampus, cerebral cortex, and serum: candidate mechanism for superior efficacy? Pharmacol Biochem Behav (2006) 84:598–608. 10.1016/j.pbb.2006.07.026
    1. Leveque JC, Macías W, Rajadhyaksha A, Carlsson RR, Barczak A, Kang S, et al. Intracellular modulation of NMDA receptor function by antipsychotic drugs. J Neurosci (2000) 20:4011–20. 10.1523/JNEUROSCI.20-11-04011.2000
    1. Spivak B, Shabash E, Sheitman B, Weizman A, Mester R. The effects of clozapine vs. haloperidol on measures of impulsive aggression and suicidality in chronic schizophrenia patients: an open, nonrandomized, 6-month study. J Clin Psychiatry (2003) 64:755–60. 10.4088/JCP.v64n0703
    1. Pompili M, Innamorati M, Raja M, Falcone I, Ducci G, Angeletti G, et al. Suicide risk in depression and bipolar disorder: do impulsiveness-aggressiveness and pharmacotherapy predict suicidal intent? Neuropsychiatr Dis Treat (2008) 4(1):247–55. 10.2147/NDT.S2192
    1. Youssef NA, Bradford DW, Kilts JD, Szabo ST, Naylor JC, Allen TB, et al. Exploratory investigation of biomarker candidates for suicide in schizophrenia and bipolar disorder. Crisis (2015) 36:46–54. 10.1027/0227-5910/a000280
    1. Pompili M, Baldessarini RJ, Forte A, Erbuto D, Serafini G, Fiorillo A, et al. Do atypical antipsychotics have antisuicidal effects? a hypothesis-generating overview. Int J Mol Sci (2016) 17(10):1700. 10.3390/ijms17101700

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir